MK2 Inhibitors as a Potential Crohn’s Disease Treatment Approach for Regulating MMP Expression, Cleavage of Checkpoint Molecules and T Cell Activity
Open Access
- 3 December 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (12) , 1508
Abstract
Crohn’s Disease (CD) and Ulcerative Colitis (UC) are the two major forms of inflammatory bowel disease (IBD), which are incurable chronic immune-mediated diseases of the gastrointestinal tract. Both diseases present with chronic inflammation that leads to epithelial barrier dysfunction accompanied by loss of immune tolerance and inflammatory damage to the mucosa of the GI tract. Despite extensive research in the field, some of the mechanisms associated with the pathology in IBD remain elusive. Here, we identified a mechanism by which the MAPK-activated protein kinase 2 (MK2) pathway contributes to disease pathology in CD by regulating the expression of matrix metalloproteinases (MMPs), which cleave checkpoint molecules on immune cells and enhance T cell activity. By utilizing pharmaceuticals targeting MMPs and MK2, we show that the cleavage of checkpoint molecules and enhanced T cell responses may be reduced. The data presented here suggest the potential for MK2 inhibitors as a therapeutic approach for the treatment of CD.Keywords
Funding Information
- Department of Defense Peer Reviewed Medical Investigator (W81XWH-22-1-0433)
This publication has 36 references indexed in Scilit:
- Inhibition of MK2 shows promise for preventing postoperative ileus in miceJournal of Surgical Research, 2013
- Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitisLaboratory Investigation, 2013
- MMPs are regulatory enzymes in pathways of inflammatory disorders, tissue injury, malignancies and remodelling of the lungEuropean Respiratory Journal, 2011
- Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epitheliumClinical and Experimental Immunology, 2008
- PD-1 Ligand Expression by Human Colonic Myofibroblasts/Fibroblasts Regulates CD4+ T-Cell ActivityGastroenterology, 2008
- A crucial role for HVEM and BTLA in preventing intestinal inflammationJournal of Experimental Medicine, 2008
- Genistein Inhibits Matrix Metalloproteinase Type 2 Activation and Prostate Cancer Cell Invasion by Blocking the Transforming Growth Factor β-Mediated Activation of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2-27-kDa Heat Shock Protein PathwayMolecular Pharmacology, 2006
- The negative regulatory function of the lymphocyte‐activation gene‐3 co‐receptor (CD223) on human T cellsImmunology, 2005
- Role of LAG-3 in Regulatory T CellsImmunity, 2004
- Fistulising Crohn's disease: MMPs gone awryGut, 2004